Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, China.
Department of General Surgery, Heilongjiang Provincial Hospital, Harbin, Heilongjiang, China.
Cancer Med. 2024 Mar;13(6):e7110. doi: 10.1002/cam4.7110.
This study aimed to investigate the prognostic significance of the Prognostic Nutritional Index (PNI) in conjunction with body composition change indices, namely subcutaneous fat area (SFA) and skeletal muscle index (SMI), with regard to clinical outcomes in patients with gastric cancer (GC) undergoing immune checkpoint inhibitors (ICIs) treatment.
This retrospective investigation encompassed patients with comprehensive clinical and pathological data, inclusive of portal phase enhanced CT images. Continuous variables underwent analysis utilizing the Student t-test or Mann-Whitney U-test, while categorical variables were assessed employing the Pearson chi-squared test or Fisher test. Survival outcomes were evaluated using Kaplan-Meier survival curves and the Log-rank test. Independent prognostic indicators were determined through Cox regression analysis, and a nomogram predicting survival probability for progression-free survival (PFS) and overall survival (OS) was constructed.
Within the PNI-SFA groups, patients in Group 1 exhibited inferior PFS and OS compared to the other two groups. Similarly, among the PNI-SMI groups, Group 1 patients demonstrated poorer PFS and OS. PNI-SMI and Eosi were identified as independent prognostic factors through Cox regression analysis. Furthermore, positive associations with patient prognosis were observed for BMI, SAF, SMI, and PNI.
The comprehensive consideration of PNI-SFA and PNI-SMI proved to be a superior prognostic predictor for GC patients undergoing ICI treatment.
本研究旨在探讨预后营养指数(PNI)与体成分变化指标(即皮下脂肪面积[SFA]和骨骼肌指数[SMI])联合用于评估接受免疫检查点抑制剂(ICI)治疗的胃癌(GC)患者临床结局的预后意义。
本回顾性研究纳入了具有全面临床和病理数据的患者,包括门静脉期增强 CT 图像。连续变量采用 Student t 检验或 Mann-Whitney U 检验进行分析,分类变量采用 Pearson 卡方检验或 Fisher 检验进行评估。采用 Kaplan-Meier 生存曲线和 Log-rank 检验评估生存结局。通过 Cox 回归分析确定独立预后指标,并构建预测无进展生存(PFS)和总生存(OS)概率的列线图。
在 PNI-SFA 组中,与其他两组相比,组 1 患者的 PFS 和 OS 较差。同样,在 PNI-SMI 组中,组 1 患者的 PFS 和 OS 也较差。通过 Cox 回归分析,PNI-SMI 和嗜酸性粒细胞计数(Eosi)被确定为独立的预后因素。此外,BMI、SFA、SMI 和 PNI 与患者预后呈正相关。
综合考虑 PNI-SFA 和 PNI-SMI 是预测接受 ICI 治疗的 GC 患者预后的更好指标。